发明名称 |
Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer |
摘要 |
Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject. |
申请公布号 |
US9623079(B2) |
申请公布日期 |
2017.04.18 |
申请号 |
US201414769069 |
申请日期 |
2014.02.26 |
申请人 |
The Board of Trustees of the Leland Stanford Junior University |
发明人 |
Willingham Stephen;Howard Maureen;Liu Jie;Majeti Ravindra;Prohaska Susan Sweeney;Volkmer Anne Kathrin;Volkmer Jens-Peter;Weissman Irving L. |
分类号 |
A61K39/395;A61K38/16;A61K38/18;C07K16/28;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Bozicevic, Field & Francis LLP |
代理人 |
Sherwood Pamela J.;Gurley Kyle A.;Bozicevic, Field & Francis LLP |
主权项 |
1. A method of treating a mammalian subject with cancer with a therapeutic dose of an anti-CD47 agent that blocks the interaction between CD47 and SIRPα, selected from: an antibody that binds to CD47; an antibody that binds to SIRPα; a soluble SIRPα-binding CD47 fragment; and a soluble CD47-binding SIRPα fragment or a combination thereof, for treatment of the cancer, the method comprising:
(a) administering a sub-therapeutic dose of one of the anti-CD47 agents to the subject, wherein the sub-therapeutic dose is effective to increase production of reticulocytes; and (b) administering a therapeutically effective dose of at least one of the anti-CD47 agents to the subject, wherein step (b) is performed in a range from about 3 days to about 21 days after beginning step (a). |
地址 |
Stanford CA US |